The prevalence of diabetes mellitus (DM) is increasing throughout the world, especially in developing countries, including India due to changing lifestyles of people and genetic background. Diabetes is disproportionately higher in the young adult population in Asian countries unlike in the West, where it is more common in older people. In 2012, 371 million people in the age group 20-79 yr were suffering from diabetes with China having maximum number followed by India[@ref1]. It will cause great economic burden on health resources worldwide especially in developing countries[@ref2]. Diabetes in India including in younger population (\<25 yr) is an alarming situation because of its economic and social impact on society[@ref2][@ref3]. Studies from India and the USA have shown increased prevalence of diabetes in younger population[@ref4][@ref5]. In India, 10 per cent of diagnosed patients with diabetes were less than 30 yr of age in 2002[@ref6]. The types of diabetes in the youth population from India was classified in to classical type 1, classical type 2, ketosis resistant youth diabetes, pancreatic diabetes or maturity onset diabetes mellitus[@ref7]. The diagnosis and classification of diabetes are based on the clinical and immunological profile of the patients. Immunological markers, such as the pancreatic islet cell antibodies, including insulin antibodies, anti-GAD, (glutamic acid decarboxylase), and anti-ICA512/IA2, an islet cell antigen are used for differentiation between different types of diabetes in the younger population. Earlier studies have reported clinical profile and variable percentages of antibody positivity in youth onset diabetes mellitus from South Asia[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]. However, none of these studies has reported all three antibodies together in youth onset diabetes mellitus in India. Genetic background predisposes a person to type 1 DM[@ref15]. However, a trigger factor is required for the onset of diabetes. The most common trigger factor is a viral infection[@ref16]. There is a paucity of data on the trigger factor for onset of type 1 diabetic from India. Therefore, the present study was aimed to evaluate clinical and immunological profile of patients with youth onset diabetes mellitus patients from north India.

Material & Methods {#sec1-1}
==================

The study subjects were part of the Protégé Encore study, a phase 3, randomized, double blind, multinational, placebo controlled study to evaluate efficacy and safety of Teplizumab (MGA031), a humanized, anti-CD3 monoclonal antibody, in children and adults with recent onset type 1 diabetes mellitus[@ref17]. The study population in this sub study was selected from Maulana Azad Medical College associated Lok Nayak Hospital, New Delhi, and Hormone Care and Research Center, Ghaziabad, Uttar Pradesh, India. The recruitment period was from January to July 2010 and sample size was based on the number of patients screened at these two centers. Participants were eligible if they met the following criteria: aged 8-35 yr; body mass of at least 36 kg; type 1 diabetes mellitus diagnosed for 12 wk or less, with need for injected insulin therapy; detectable fasting or stimulated C-peptide; and positive autoantibody titre against an islet-cell antigen (ICA-512/IA-2), glutamic acid decarboxylase (GAD 65), or insulin, within 2 wk of initiating insulin treatment. Exclusion criteria focused on medical disorders that would potentially confound results or interfere with safe completion of the trial, including serious cardiovascular disorders, active infections, and recent participation in a clinical trial, vaccination, or pregnancy. Criteria for diagnosis of diabetes were as per standard American Diabetes Association (ADA) guidelines[@ref18].

All study patients were subjected to clinical and biochemical tests as per pre-designed case record form. The laboratory tests included complete blood count, blood glucose levels, kidney and liver function tests, lipid profile, HbA~1~c, and urine for micro-HbA~1~c albumin. Immunological profile included detection of antibodies against glutamic acid decarboxylase (GAD Ab), a tyrosine phosphatase-like protein (ICA 512/IA-2 Ab) and insulin by ELISA method and insulin antibodies were done by radioimmunoassay (RIA) method from kits supplied by Kronus (Boise, USA). The levels of three autoantibodies were measured in a licensed central laboratory (Quintiles Laboratories, Singapore). The cut-off values for GAD Ab, ICA512/IA-2 and insulin antibodies were 5 IU/ml, 15 and 0.4 U/ml, respectively. All three kits were tested for performance qualification before study sample analysis. Calibration verification, sensitivity, precision, and dilution verification were evaluated. The immunological profile for anti-GAD, anti-ICA512/IA-2 and anti-insulin antibodies was done in all patients. The patients having antibodies alone or combination were considered as suffering from type 1 DM and the remaining patients were classified as type 2 DM.

Further, all patients were tested for active viral infections such as, hepatitis A-E, cytomegalovirus (CMV), and Epstein-Barr virus (EBV) by antigen detection methods. Hepatitis A antibody total (anti-HAV total) and hepatitis A IgM antibody (anti-HAV, IgM) were tested by Bayer Chemiluminescence. Qualitative immunoassay was used for the hepatitis screen panel (HBsAg, anti-HCV). Hepatitis B surface antigen (HBsAg) confirmation was tested by Bayer Chemiluminescence. HCV RIBA was done by National University Hospital (Singapore). Diasorin EIA (enzyme immunoassay) was used for hepatitis D (Delta) antibody (anti-D) detection and hepatitis E IgG antibodies were done by Metropolis (Mumbai, India). Epstein-Barr virus and CMV were tested using polymerase chain reaction (PCR). IgM and IgG antibodies for EBV and IgG antibodies for CMV were tested in all patients by EIA and immunoflourescence, respectively. Institutional ethics committee approved the study protocol, and all participants or guardians gave written informed consent.

*Statistical analysis*: Data were analyzed using SSPS for windows 10. Statistical methods used were descriptive to calculate mean ± SD.

Results {#sec1-2}
=======

The baseline characteristics of subjects are given in the [Table](#T1){ref-type="table"}. Of the total 51 subjects, 38 were men and 13 were women. The mean age was 19.72±7.14 yr, and BMI was 21.02±4.57 kg/m^2^. Twenty subjects were below the age 18 and their height was more than 75^th^ percentile of Indian standards. Eleven subjects who were less than 18 yr of age had a height of \>75 % percentile as per Indian growth charts. There was no significant difference in different parameters in type 1 and type 2 subjects except the age was significantly (*P*\<0.05) higher in type 2 group. All subjects were symptomatic for diabetes and 12 of these patients presented with ketoacidosis at the time of diagnosis. The remaining patients presented with osmotic symptoms. There was no sign of neuropathy, retinopathy, and nephropathy in these patients at the time of inclusion. Mean HbA~1~c level of all patients was 11.55 per cent. All patients had normal blood counts, lipid profile, and kidney and liver function tests. Mean thyroid stimulating hormone (TSH) level was 11.03±36.49 uIU/ml. Only 12 per cent patients had hypothyroidism.
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Anti-GAD Ab was present in 24 (48%) patients. ICA512/IA2 antibody was detected in seven (14%) patients, and 14 (28%) patients had insulin antibodies. Seven (14%) patients showed presence of both anti-GAD and anti-ICA512/IA2 antibodies and five (9%) patients had both anti-GAD and insulin antibodies. Presence of all three pancreatic antibodies was observed in only three patients.

Antibody-positive patients were younger, had a lower weight and BMI, and most of them presented with diabetic ketoacidosis. There was evidence of active hepatitis E (IgM antibody positive) infection in five patients. None of the patients showed evidence of active CMV, EBV infection or other hepatitis infection.

Discussion {#sec1-3}
==========

The differentiation between T1DM and T2DM is difficult in young patients but can be done by immunological markers, such as anti-GAD, ICA512/IA2, and insulin antibodies[@ref19]. In our study, anti-GAD antibodies were present in 48 per cent patients, ICA512/IA2 antibody in 14 per cent and insulin antibody in 28 per cent cases of youth onset diabetes. Further, active viral infection, especially HEV as a possible trigger factor for onset of T1DM was observed in only 10 per cent of cases.

Autoimmunity in youth onset has been reported earlier from India and elsewhere[@ref11][@ref12][@ref13]. The level of autoimmunity reported in the present study was among the highest reported so far compared to other Indian studies[@ref7][@ref8][@ref9]. Kouchipillai *et al*[@ref6] have shown 38 per cent anti-GAD positivity in their study. However, Pan *et al*[@ref20] reported prevalence as low as 9 per cent in South Indian patients[@ref13]. A study from north India has shown higher values, *i.e*. 70 per cent of GAD positivity and 20-26 per cent positivity of ICA antibody in type1diabetic patients[@ref20]. Goswami *et al*[@ref7] have reported 24.2 per cent pancreatic antibody in youth onset diabetes patients from north India. Other studies such as by Tica *et al*[@ref21] and Thai *et al*[@ref22] have reported 27 and 39.6 per cent positivity of anti-GAD, respectively. Lan *et al*[@ref23] reported 54.6 per cent positivity for anti-GAD and 24 per cent for both anti-GAD and ICA512/IA2 antibodies. Presence of all three antibodies was observed in only three patients. None of the studies have analyzed all antibodies together for diagnosis of type1diabetes. In our study, anti-GAD antibody was present in all antibody positive youth onset DM. Therefore, testing for anti-GAD Ab alone may perhaps suffice as a diagnostic tool in youth onset DM.

Another interesting fact in our study was that five patients of type 1 DM had evidence of active HEV infection. None of the patients showed evidence of recent EBV and CMV virus infections. There are at least two different pathogenic mechanisms in virus-induced diabetes: cytolytic infection of beta cells leading to their destruction, and triggering of autoimmunity leading to the autoimmune-mediated destruction of beta cells[@ref24]. At least 10 viruses have been implicated as triggering factors in the onset of T1DM. Retrovirus, mumps virus, rubella virus, CMV, enterovirus and EBV are responsible for autoimmune-mediated destruction of beta cells. Other viral infections such as encephalomyocarditis virus, Coxsackie B viruses can lead to direct damage to beta cell[@ref25][@ref26][@ref27][@ref28][@ref29]. In our study, only five patients had evidence of HEV infection suggesting its possible role in onset of autoimmune DM in youth. Hepatitis C virus infection has been shown to have a role in the development of T1DM[@ref30][@ref31]. However, another study did not find any correlation between any of the viral hepatitis infections and onset of DM[@ref32].

In this study the height of T1DM patients was more than 75 per cent percentile of Indian standard. The increase in height may be attributed to autoimmune phenomenon functioning in growth acceleration as well as production in antibodies in T1DM[@ref33].

Our study had certain limitations. We have not done HLA-typing in this study. Further, there was a selection bias as we excluded subjects with signs of insulin resistance.

In conclusion, the presence of pancreatic antibodies was seen among half of the youth onset diabetic patients from north India, anti-GAD Ab being the most common. Similar studies should be done in other parts of the country with a large sample size.
